Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting adenovirus.

T J Wickham1

  • 1Vector Targeting and Selectivity, GenVec Inc, 12111 Parklawn Drive, Rockville, MD 20852, USA.

Gene Therapy
|February 16, 2000
PubMed
Summary
This summary is machine-generated.

Targeted adenovirus vectors offer improved gene therapy by localizing gene transfer, reducing side effects, and enabling systemic administration for diseases like cancer. Development focuses on modifying adenovirus to bind specific tissues, enhancing safety and efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors.

CPT: pharmacometrics & systems pharmacology·2013
Same author

Gamma-irradiation enhances transgene expression in leukemic cells.

Gene therapy·2003
Same author

Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions.

Journal of virology·2001
Same author

Transduction and apoptosis induction in the rat prostate, using adenovirus vectors.

Human gene therapy·2001
Same author

Adenovirus type 9 fiber knob binds to the coxsackie B virus-adenovirus receptor (CAR) with lower affinity than fiber knobs of other CAR-binding adenovirus serotypes.

Journal of virology·2001
Same author

Efficient transduction of murine B lymphocytes and B lymphoma lines by modified adenoviral vectors: enhancement via targeting to FcR and heparan-containing proteins.

Gene therapy·2001
Same journal

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Gene therapy·2026
Same journal

Recent advancements in improving cross-species applicability of bioengineered AAV capsids.

Gene therapy·2026
Same journal

Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.

Gene therapy·2026
Same journal

Applications of genome editing technologies in the treatment of human diseases.

Gene therapy·2026
Same journal

High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.

Gene therapy·2026
Same journal

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice.

Gene therapy·2026
See all related articles

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Virology

Background:

  • Conventional gene therapy vectors face limitations in specificity and safety.
  • Targeted adenovirus vectors aim to overcome these limitations by localizing gene transfer.
  • Adenovirus structure and receptor interactions are key to developing targeted vectors.

Purpose of the Study:

  • To review the development and approaches for creating targeted adenovirus vectors.
  • To highlight the advantages of targeted vectors over non-targeted ones.
  • To discuss future challenges and potential improvements in targeted adenovirus technology.

Main Methods:

  • Two primary approaches for targeted adenovirus vector development: 'two-component' and 'one-component' systems.
  • The 'two-component' approach uses a bispecific molecule to block native binding and redirect to specific receptors.

Related Experiment Videos

  • The 'one-component' approach genetically modifies the adenovirus to remove native interactions and incorporate new ligands.

    • Main Results:

    • Targeted adenovirus vectors show potential to reduce immunogenicity and toxicity.
    • These vectors may enable systemic administration for treating cancer, cardiovascular, and inflammatory diseases.
    • Two-component systems offer flexibility for receptor targeting validation, while one-component systems are better for manufacturability.

    Conclusions:

    • Targeted adenovirus vectors represent a significant advancement in gene therapy.
    • Demonstrating in vivo efficacy is a critical next step for these vectors.
    • Combining receptor-targeting with improved backbones and transcriptional targeting will enhance selectivity and safety.